IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Medicamen Organics IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in New Delhi and caters to Pharmaceutical sector. GYR Capital Advisors Private is the merchant banker of Medicamen Organics IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 21st February 2024.
Medicamen Organics IPO posted revenues of Rs 25.28 crores and PAT of Rs 2.40 crores in FY25 on annualised basis.Financial results of Medicamen Organics IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Medicamen Organics IPO PAT Margin is 9.50%, ROCE (Return on Capital Employed) is 14.50% as per latest financial. The below table shows Medicamen Organics IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Medicamen Organics IPO is Rs 39.78 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Medicamen Organics IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Medicamen Organics IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Medicamen Organics IPO is ₹39.78 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Medicamen Organics IPO has a Price-to-Earnings (PE) ratio of 15.41 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Medicamen Organics IPO reported revenue of ₹25.28 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Medicamen Organics IPO provide insights into sales growth, market demand, and business scalability.
Medicamen Organics recorded an EBITDA of ₹ 4.76 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Medicamen Organics Profit After Tax (PAT) is ₹2.40 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 25.27 Cr.
EBITDA Margin:
18.84
%
Net Worth: ₹ 15.18 Cr.
Market Capitalisation:
₹ 39.78 Cr.
P/E:
15.41 times
P/BV: 1.55 times
EV/EBITDA: 10.90 times
Medicamen Organics operates in Pharmaceutical and Manufactures, And Distributes Pharmaceutical Dosages. The Issue is listed on NSE EMERGE in Jun, 2024. Medicamen Organics IPO size was 10.54 with Issue price of 34.00 .
Merchant Banker(s) of Medicamen Organics IPO: GYR Capital Advisors Private Limited
Medicamen Organics IPO subscription was 993.56 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Medicamen Organics IPO listed at a listing price of 144.70 against the offer price of 34.00.
The current market price of Medicamen Organics is 28.95.
Why Us?
